Insight Molecular Diagnostics (FRA:7OC0) Cyclically Adjusted Book per Share: €8.42 (As of Mar. 2026)


FRA:7OC0 Insight Molecular Diagnostics Inc FRA:7OC0
49 GF Score
Price €4.14
GF Value €1.02
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Cyclically Adjusted Book per Share?

Insight Molecular Diagnostics FRA:7OC0 -1.43% 49 Cyclically Adjusted Book per Share is €8.42 as of Mar. 2026. GuruFocus rates FRA:7OC0 with a GF Score™ of 49/100 and a GF Value™ of €1.02. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Insight Molecular Diagnostics's adjusted book value per share for the three months ended in Mar. 2026 was €-0.286. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.42 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Insight Molecular Diagnostics's average Cyclically Adjusted Book Growth Rate was -7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-12), Insight Molecular Diagnostics's current stock price is €4.14. Insight Molecular Diagnostics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €8.42. Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio of today is 0.49.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insight Molecular Diagnostics was 0.82. The lowest was 0.20. And the median was 0.34.


Insight Molecular Diagnostics  (FRA:7OC0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.14/8.42
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Insight Molecular Diagnostics was 0.82. The lowest was 0.20. And the median was 0.34.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Insight Molecular Diagnostics Cyclically Adjusted Book per Share Related Terms


Insight Molecular Diagnostics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Cyclically Adjusted Book per Share Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 12.89 6.57

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.90 9.87 8.81 6.57 8.42

FRA:7OC0 vs XGN, BDSX, BNR: Cyclically Adjusted Book per Share Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Cyclically Adjusted PB Ratio falls into.


FRA:7OC0
49GF Score
Insight Molecular Diagnostics Inc FRA:7OC0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insight Molecular Diagnostics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.286/330.2130*330.2130
=-0.286

Current CPI (Mar. 2026) = 330.2130.

Insight Molecular Diagnostics Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.126 241.018 4.283
201609 7.879 241.428 10.776
201612 6.506 241.432 8.898
201703 5.588 243.801 7.569
201706 3.400 244.955 4.583
201709 4.298 246.819 5.750
201712 2.366 246.524 3.169
201803 3.869 249.554 5.120
201806 2.975 251.989 3.899
201809 3.171 252.439 4.148
201812 1.480 251.233 1.945
201903 13.003 254.202 16.891
201906 11.409 256.143 14.708
201909 10.249 256.759 13.181
201912 9.731 256.974 12.504
202003 10.610 258.115 13.574
202006 10.461 257.797 13.400
202009 8.745 260.280 11.095
202012 7.964 260.474 10.096
202103 20.146 264.877 25.115
202106 18.869 271.696 22.933
202109 18.326 274.310 22.061
202112 12.515 278.802 14.823
202203 11.216 287.504 12.882
202206 13.280 296.311 14.799
202209 13.088 296.808 14.561
202212 5.457 296.797 6.071
202303 5.940 301.836 6.498
202306 4.883 305.109 5.285
202309 4.261 307.789 4.571
202312 2.272 306.746 2.446
202403 1.289 312.332 1.363
202406 1.578 314.175 1.659
202409 0.654 315.301 0.685
202412 -0.672 315.605 -0.703
202503 0.331 319.799 0.342
202506 0.033 322.561 0.034
202509 -0.274 324.800 -0.279
202512 -0.937 324.054 -0.955
202603 -0.286 330.213 -0.286

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €8.42 mean?
Insight Molecular Diagnostics (FRA:7OC0) has a Cyclically Adjusted Book per Share of €8.42 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Cyclically Adjusted Book per Share too high?
Insight Molecular Diagnostics' current Cyclically Adjusted Book per Share is €8.42. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Cyclically Adjusted Book per Share compare to XGN and BDSX?
Insight Molecular Diagnostics' Cyclically Adjusted Book per Share of €8.42 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Book per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Cyclically Adjusted Book per Share is €8.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Insight Molecular Diagnostics (FRA:7OC0) has a current Cyclically Adjusted Book per Share of €8.42. The stock's GF Value™ is €1.02, compared to a current price of €4.14 — trading 305.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €8.42. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Insight Molecular Diagnostics (FRA:7OC0), the current Cyclically Adjusted Book per Share is €8.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (FRA:7OC0) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of €4.14 is trading 305.9% above its estimated GF Value™ of €1.02.

Key valuation signals for FRA:7OC0:

  • Cyclically Adjusted Book per Share: €8.42
  • GF Value™: €1.02 vs. price of €4.14 (305.9% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the FRA:7OC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges IMDX:USA0KCC:UK
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for FRA:7OC0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.14
Price
€1.02
GF Value